Indefinite Delivery Contract 75F40121D00009
Award Date
6/3/21
Last Date to Order
6/14/26
Federal Agency
Food and Drug Administration
Awardee
Qiagen, LLC
Ultimate Awardee
Qiagen N.V.
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Headquarters Division of the Federal Bureau of Investigation (FBI) to Qiagen, LLC, a division of Qiagen N.V. The $2,500,000 single-award contract has a period of performance through April 2030 and provides for the acquisition of QIAGEN consumables and reagents. Qiagen, as a supplier of sample and assay technologies, has a history of providing products and services in support of federal agencies' biomedical research, public health, law...
The U.S. Food and Drug Administration (FDA), a civilian agency, has awarded an Indefinite Delivery Contract to Illumina, Inc., a manufacturer of genetic sequencing and genomic analysis instruments and reagents. The contract has a ceiling value of $25,000,000 and a period of performance through January 29, 2028. Under this contract, Illumina will provide the FDA with a variety of its proprietary reagent chemistry kits and associated consumables to support the agency's laboratory testing,...
The Department of Health and Human Services Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract (IDC) to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the provision of Reagent (Chemistry) Kits. The single-award IDC has a ceiling value of $19,500,000 and an ultimate completion date of September 14, 2022. Under this contract, the FDA has issued a series of firm fixed-price delivery orders to Illumina for the supply of various chemistry...
This Indefinite Delivery Contract (IDC) was awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents. The $992,022 IDC provides for the delivery of NextSeq 500 High Output Reagent Kits to support the FDA's nucleic acid sequencing needs, with no set-aside provisions. Three delivery orders have been issued against the IDC, valued at $38,896, $193,380, and $237,188 respectively, for the purchase of...
The U.S. Food and Drug Administration (FDA) has awarded a $1 million single-award Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Pacific Biosciences of California, Inc. to provide sequencing reagents, kits, and consumables to support the agency's genomic research and regulatory review activities. Under this contract, the FDA has issued multiple delivery orders for the purchase of Pacific Biosciences' proprietary single molecule, real-time (SMRT) sequencing consumables, including...
This federal contract IDV award from the Defense Health Agency (DHA) is a $7,433,000 Blanket Purchase Agreement (BPA) with Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics and laboratory equipment. The BPA has a period of performance through October 2028 and allows the DHA to efficiently acquire a range of specialized reagents, consumables, and kits to support the agency's biomedical research, public health, and healthcare initiatives. Task orders issued under...
This Blanket Purchase Agreement (BPA) contract, awarded by the National Institute of Environmental Health Sciences and other civilian federal agencies, provides a vehicle for the recurring procurement of specialized medical and scientific products and services from Qiagen, LLC, a foreign-owned for-profit manufacturer. The primary products and services being delivered under this IDV include DNA/RNA extraction kits, next-generation sequencing equipment, bioinformatics software, chemical...
Qiagen, LLC was awarded a single award blanket purchase agreement by the Department of Health and Human Services Centers for Disease Control and Prevention. The agreement has a potential value of $250,000 and a period of performance through June 2021. Under the blanket purchase agreement, Qiagen will provide its portfolio of sample and assay technologies to support the Centers for Disease Control and Prevention's biomedical research and public health programs. This includes DNA/RNA extraction...
The Department of Health and Human Services Centers for Disease Control and Prevention has awarded a single-award Blanket Purchase Agreement (BPA) to Qiagen, LLC, a foreign-owned for-profit manufacturer, to provide ONE STEP RT PCR KIT. The $49.2 million BPA has a period of performance through December 31, 2021. Qiagen, a provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academia, has a history of delivering a range of products and services to...
The Department of Health and Human Services Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract (IDC) to Biomerieux Inc., a global leader in in vitro diagnostics, with a ceiling value of $2,000,000. The contract provides the FDA with access to Biomerieux's specialized diagnostic platforms, reagents, and test kits to support the agency's medical device testing, pathogen detection, and clinical laboratory operations. Through a series of firm-fixed-price delivery orders...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 75F40121D00009-75F40122F19002 | Qiagen, LLC | $149.0k | 5/26/22 | 9/26/22 | 5/26/22 | |
Delivery Order 75F40121D00009-75F40124F19005 | Qiagen, LLC | $93.1k | 8/2/24 | 6/14/25 | 8/2/24 | |
Delivery Order 75F40121D00009-75F40123F19003 | Qiagen, LLC | $147.9k | 6/8/23 | 6/14/24 | 5/7/25 | |
Delivery Order 75F40121D00009-75F40125F19006 | Qiagen, LLC | $33.9k | 7/2/25 | 9/29/25 | 7/2/25 | |
Delivery Order 75F40121D00009-75F40121F19001 | Qiagen, LLC | $158.2k | 6/23/21 | 7/11/22 | 10/24/23 |